Guardian Pharmacy Services, backed by Bindley Capital Partners, has priced a 6 million share offering at $31 per share, valuing the deal at approximately $186 million. The Atlanta-based long-term care pharmacy company announced the 'synthetic secondary' offering will close on March 20, 2026. This follows the company's September 2024 IPO, which raised $112 million on the New York Stock Exchange under the ticker symbol GRDN.

Certain stockholders will sell nearly 5 million shares in the transaction, while Guardian plans to use all net proceeds to repurchase over one million shares of common stock at the public offering price. BofA Securities, Jefferies, and Raymond James are serving as main underwriters, with Stephens Inc. and Oppenheimer & Co. acting as co-managers. The offering represents a significant liquidity event for early investors in the Bindley Capital-backed company.

The secondary offering comes as Guardian continues expanding its footprint in the specialized pharmacy services market for long-term care facilities. By repurchasing shares alongside the secondary sale, the company aims to streamline its capital structure while providing existing investors with an exit opportunity. This strategic move reflects growing investor interest in healthcare services companies following Guardian's successful public market debut.